OncLive | BOLERO-3 Safety Analysis Finds Everolimus Regimen Is Manageable OncLive The combination of everolimus, trastuzumab, and vinorelbine, as given in the BOLERO-3 trial in patients with pretreated HER2-positive advanced breast cancer, is adequately tolerated, and adverse events are manageable, according to a safety analysis of ... |
